Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ.

Cancer Res. 2008 Jul 1;68(13):5469-77. doi: 10.1158/0008-5472.CAN-08-0594.

2.

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

Marcias G, Erdmann E, Lapouge G, Siebert C, Barthélémy P, Duclos B, Bergerat JP, Céraline J, Kurtz JE.

Hum Mutat. 2010 Jan;31(1):74-80. doi: 10.1002/humu.21138.

PMID:
19830810
3.

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM.

Oncogene. 2012 Nov 8;31(45):4759-67. doi: 10.1038/onc.2011.637. Epub 2012 Jan 23.

4.

Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.

Mashima T, Okabe S, Seimiya H.

Mol Pharmacol. 2010 Nov;78(5):846-54. doi: 10.1124/mol.110.064790. Epub 2010 Aug 13.

5.

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM.

Cancer Res. 2011 Mar 15;71(6):2108-17. doi: 10.1158/0008-5472.CAN-10-1998. Epub 2011 Jan 19.

6.

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.

Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.

7.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

8.

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.

Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ.

Cancer Res. 2002 Nov 15;62(22):6606-14.

9.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

10.

Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.

Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL.

Oncotarget. 2015 Oct 13;6(31):31997-2012. doi: 10.18632/oncotarget.5585.

11.

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J.

Cancer Res. 2009 Jan 1;69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764.

12.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

13.

Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ.

Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Review.

14.

The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.

Kim Y, Kim J, Jang SW, Ko J.

Oncogene. 2015 Jan 8;34(2):226-36. doi: 10.1038/onc.2013.538. Epub 2014 Jan 20.

PMID:
24441043
15.

Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.

Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M.

Cancer Res. 2007 Oct 1;67(19):9001-5.

16.

Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Krause WC, Shafi AA, Nakka M, Weigel NL.

Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.

17.
18.

Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.

He HJ, Gu XF, Xu WH, Yang DJ, Wang XM, Su Y.

Acta Pharmacol Sin. 2013 Feb;34(2):282-8. doi: 10.1038/aps.2012.130. Epub 2012 Oct 1.

19.

Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.

Pignon JC, Koopmansch B, Nolens G, Delacroix L, Waltregny D, Winkler R.

Cancer Res. 2009 Apr 1;69(7):2941-9. doi: 10.1158/0008-5472.CAN-08-3760. Epub 2009 Mar 24.

Supplemental Content

Support Center